LYEL
Lyell Immunopharma Inc
9.10$
-2.1%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.9% | -0.7% | -2.4% | -4.5% | +7.4% | -31.5% | -8.9% | -18.1% | -6.6% | -2.7% | -4.7% | – | |
| – | -19.5% | +8.2% | -9.5% | -8.0% | +6.0% | -25.5% | -16.9% | +4.6% | +388.7% | -83.2% | +5.5% | – | |
| – | -29.0% | -288.0% | – | – | -96.7% | -28,200.0% | – | – | – | -261.3% | – | – | |
| – | -87.2% | +20.0% | +1,003.3% | -82.2% | -25.4% | +459.1% | -31.7% | -63.1% | +390.3% | -70.7% | +187.6% | – | |
| – | -201.0% | – | +104.6% | -95.7% | +2,689.6% | +29.8% | -81.8% | -73.5% | -1,036.5% | – | -10.1% | – | |
| – | -42.8% | -38.2% | – | -190.6% | – | – | – | – | – | – | – | – | |
| – | – | -96.4% | +3,092.6% | -100.0% | – | -99.8% | +18,200.0% | +27,222.4% | -99.6% | +23,198.2% | -99.0% | – | |
| – | -327.3% | – | – | -526.1% | – | +178.0% | -246.8% | – | -355.9% | – | -158.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.